# Antibodies Response to mRNA Vaccine Against Covid-19

> **NCT04733807** · — · UNKNOWN · sponsor: **University of Roma La Sapienza** · enrollment: 600 (estimated)

## Conditions studied

- Covid-19

## Interventions

- **BIOLOGICAL:** BNT162b2 mRNA Covid-19 Vaccine

## Key facts

- **NCT ID:** NCT04733807
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-28
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-02-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733807, "Antibodies Response to mRNA Vaccine Against Covid-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04733807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*